Paper Details

  1. Home
  2. Paper Details

Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer.

Author: BasketterVanessa, Burns-CoxNick, HigginsBernard, HolmesSimon

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Diethylstilboestrol (DES) treatment for hormone relapsed prostate cancer (HRPC) is associated with a greater PSA fall and an increase in median survival compared to flutamide treatment. The median survival was 18 months for DES group and 11 months for flutamide group.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Patients with hormone relapsed prostate cancer (HRPC) are often treated with flutamide or diethylstilboestrol. However, which of these two options is the best treatment for HRPC remains unclear. METHODS: We carried out a prospective study to determine and compare the prostate-specific a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1442-2042.2002.00495.x

データ提供：米国国立医学図書館（NLM）

A Race Through the Desert: Comparing Diethylstilboestrol and Flutamide in Treating Hormone-Relapsed Prostate Cancer

The [battle against prostate cancer] is a relentless journey through the vast desert of [oncology]. This study investigates the [efficacy] of [diethylstilboestrol (DES) and flutamide] in treating [hormone-relapsed prostate cancer (HRPC)]. The researchers conducted a [prospective randomized trial] with [28 patients] to [compare the two treatments] and found that [DES was associated with a greater PSA fall and a longer median survival]. Additionally, the study found no difference in [quality of life] between the two groups.

Finding Oasis in the Desert: Diethylstilboestrol Shows Promise for Hormone-Relapsed Prostate Cancer Treatment

The results suggest that [DES] may offer a more [effective treatment option] for [HRPC] compared to [flutamide], demonstrating a [significant reduction] in [PSA levels] and a [potential increase] in [survival time]. This discovery is encouraging in the fight against prostate cancer and offers a new avenue for exploration.

Navigating the Desert of Prostate Cancer: Understanding the Implications of Diethylstilboestrol

While the study shows promising results for [DES], it's essential to remember that [this treatment option] is not a cure and may not be suitable for all patients. It's crucial to consult with a qualified oncologist to determine the best course of treatment for your individual situation.

Dr.Camel's Conclusion

The desert of prostate cancer is vast and unforgiving, but this study highlights the potential for a new oasis of hope in the form of diethylstilboestrol. While more research is needed, these promising results suggest that DES may offer a more effective treatment option for hormone-relapsed prostate cancer. It's a reminder that even in the most challenging battles, we can find new paths towards better health.

Date :
  1. Date Completed 2003-03-03
  2. Date Revised 2019-09-22
Further Info :

Pubmed ID

12225339

DOI: Digital Object Identifier

10.1046/j.1442-2042.2002.00495.x

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.